Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» MASH
MASH
Boehringer signs $1.3B deal with RNA biotech Ochre Bio to team up against MASH
Fierce Biotech
Mon, 04/22/24 - 11:44 am
Boehringer Ingelheim
Ochre Bio
RNA
MASH
NASH
5 Promising MASH Therapies That Could Follow Madrigal’s Rezdiffra
BioSpace
Mon, 04/15/24 - 11:24 am
MASH
NASH
Madrigal Pharmaceuticals
Rezdiffra
Ionis Pharmaceuticals
ION224
Altimmune
pemvidutid
89Bio
pegozafermin
Viking Therapeutics
VK2809
Aligos Therapeutics
ALG-055009
D&D Pharmatech Granted Fast Track Designation from US FDA for DD01 for the Treatment of NASH/MASH
BioSpace
Tue, 04/2/24 - 11:37 am
D&D Pharmatech
DD01
MASH
NASH
FDA
fast track
89bio wins EMA priority status for MASH candidate pegozafermin
Clinical Trials Arena
Thu, 03/28/24 - 11:21 am
89Bio
Europe
EMA
pegozafermin
MASH
Madrigal’s Rezdiffra Energizes MASH Space, Sets Bar for Future Therapies
BioSpace
Mon, 03/18/24 - 11:25 am
Madrigal Pharmaceuticals
Rezdiffra
NASH
MASH
Madrigal wins FDA approval of first drug for MASH
BioPharma Dive
Thu, 03/14/24 - 06:27 pm
Madrigal Pharmaceuticals
FDA
Rezdiffra
MASH
NASH
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial
Reuters
Wed, 03/13/24 - 10:43 am
Ionis Pharmaceuticals
MASH
NASH
clinical trials
ION224
89bio kicks off Phase III trial for pegozafermin in MASH
Clinical Trials Arena
Tue, 03/12/24 - 06:51 pm
89Bio
clinical trials
pegozafermin
MASH
NASH
Akero, bruised from earlier failure, soars as liver scarring improves in longer MASH trial
Fierce Biotech
Mon, 03/4/24 - 11:21 am
Akero Therapeutics
efruxifermin
MASH
NASH
Boehringer’s survodutide shows monster MASH potential
Pharmaphorum
Mon, 02/26/24 - 10:36 am
Boehringer Ingelheim
weight loss
MASH
NASH
survodutide
Sagimet stock doubles as phase 2b MASH trial hits primary goals, despite dropout queries
Fierce Biotech
Mon, 01/22/24 - 11:06 am
Sagimet Biosciences
clinical trials
MASH
NASH
denifanstat
Novo Nordisk offers 2 Flagship biotechs up to $1B total for obesity, MASH deals
Fierce Biotech
Thu, 01/4/24 - 10:06 am
Novo Nordisk
Omega Therapeutics
Cellarity
Flagship Pioneering
funding
obesity
NASH
MASH